A carregar...
Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
ROS1 inhibition provides impressive survival benefits in ROS1-rearranged non-small cell lung cancer (NSCLC) patients. Crizotinib is the only tyrosine kinase inhibitor (TKI) approved by both FDA and EMA for the treatment of ROS1-positive lung cancer. In addition, several TKI have been tested with pre...
Na minha lista:
| Publicado no: | Lung Cancer (Auckl) |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6747675/ https://ncbi.nlm.nih.gov/pubmed/31572036 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S190786 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|